« back to GLOBAL TRANSPARENCY PAGE

Estonia
transparency obligations overview

Latest update: 18 December 2018 | Important Notes
PHARMACUETICAL
MEDICAL DEVICE

Pharmaceutical Companies

What is reported:

Law: By 1 February each year, the holder of a marketing authorisation for a medicinal product must submit to the State Agency of Medicines a report concerning support awarded the previous year under subsections 86 (2: gifts) and (5: support a medical or pharmaceutical event organised by a research institution or professional organisation) of the Medicinal Products Act to pharmacists, assistant pharmacists, persons qualified to prescribe medicinal products and their associations for the purpose of participation in or organisation of medical or pharmaceutical events, and on the meetings and patient information events organised, samples distributed and discounts made based on subsection (6) of the same section. A report on advertising of medicinal products submitted by a marketing authorisation holder is public information.

Code: Payments made either directly or indirectly to healthcare professionals, pharmacists or healthcare organizations during a calendar year shall be disclosed six months after the end of financial year on the APME member companies’ website according to the APME ethical code Appendix C methodology and Table C1 Data disclosure form.

Payments referred to in the previous sentence (hereinafter referred to as “payments”) paid to healthcare professionals, pharmacists, healthcare organizations or to third parties on their behalf (for example, to service providers such as accommodation establishments), including:

  • Registration fees for events (e.g. conferences)
  • Travel and accommodation expenses for events
  • Service or consultancy fees
  • Studies or development related fees
  • Payments to healthcare organizations:
    1. Donations
    2. Grants

Medical Device Companies

If applicable (e.g. if your company is a member of MedTech or an industry association that is a member of MedTech): kindly refer to ‘Europe – Medical Device Companies’ for the summary in line with the MedTech Europe Code of Ethical Business Practice.

MedTech Baltics is a member of MedTech (see: https://www.medtecheurope.org/about-us/members/).

According to the MedTech Europe Code, National Associations shall transpose their Code at the national level by 1 January 2020.

What is Reported:

If not already obliged by local laws/regulations, companies need to make public the aggregate spend regarding educational grants on a yearly basis.

Important notes:
  • This information is provided for your convenience and should not be construed as legal advice. The applicability of these requirements to your organization depends on individual circumstances. The information is not exhaustive.
  • Kindly check with your legal department and do not depend solely on the information provided here. Moreover, the rules mentioned could be subject to interpretation of local authorities/courts in the applicable jurisdiction. Lastly, be mindful of the latest update mentioned above. These rules and regulations change frequently, so it is important to determine whether the information provided reflects the most recent changes and is still applicable.
  • Reporting dates are related to the transparency obligation regarding transfers of value by pharmaceutical companies and/or medical device companies (excluding suppliers of in vitro diagnostics) to HCPs and HCOs. These often are based on laws or rules in codes of conduct of industry associations. In case it is based on codes of conduct, your company only needs to disclose the transfers of value on the mentioned due date if your company is a member of the association that follows that code.
  • Including a jurisdiction in the Legislative Watch does not guarantee that jurisdiction is available for reporting via the MediSpend Transparency Reporting Solution.
  • Reporting date normally means the date the transfers of value need to be published. The deadline for e.g. submission/sending the complete information to the authority could be before that date, for example to give HCPs and/or HCOs and/or the authority/association who publishes the information, the possibility to check the data the pharmaceutical companies/medical device companies are going to disclose.
  • The information does not take into consideration (unless explicitly mentioned):
    • Transparency related to clinical trials (unless it concerns transfers of value as mentioned above)
    • Transparency related to patient organizations (unless the patient organization is considered an HCO)


Disclaimer:

The information contained in this website is for general information purposes only. The information is provided by MediSpend and, while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is, therefore, strictly at your own risk.

In no event will MediSpend be liable for any loss or damage including, without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you may be able to link to other websites which are not under the control of MediSpend. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, MediSpend takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.